| Male (n=11) | Female (n=38) | P-Value | |
|---|---|---|---|
| Immunodominant Antibody MFI Pre-Treatment | 12613 ± 3642 | 12779 ± 3498 | 0.891 |
| Immunodominant Antibody MFI Post-Treatment | 12045 ± 3514 | 12055 ± 3925 | 0.994 |
| Change in Immunodominant Antibody MFI | -568 ± 1687 | -723 ± 1782 | 0.798 |
| Average Time on Waitlist (years) | 0.61 ± 0.62 | 0.65 ± 0.82 | 0.896 |
| 1-Year Survival | 100.0% | 89.5% | 0.299 |
| 1-Year Freedom from Acute Cellular Rejection (ACR) | 81.8% | 94.7% | 0.106 |
| 1-Year Freedom from Antibody-Mediated Rejection (AMR) | 72.7% | 78.9% | 0.691 |